Evidence map›Paper›PMID 34424374›Full record

ArticleWorld journal of urology2022

Market potentials of robotic systems in medical science: analysis of the Avatera robotic system.

Evangelos Liatsikos, Arman Tsaturyan, Iason Kyriazis, Panagiotis Kallidonis, Dimitris Manolopoulos, Anastasios Magoutas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Comparison between DaVinciJournal of robotic surgery · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Evangelos LiatsikosDepartment of Urology, University of Patras Medical School, University of Patras, Rio, 26500, Patras, Greece. liatsikos@yahoo.com.
Arman TsaturyanDepartment of Urology, University of Patras Medical School, University of Patras, Rio, 26500, Patras, Greece.
Iason KyriazisDepartment of Urology, University of Patras Medical School, University of Patras, Rio, 26500, Patras, Greece.
Panagiotis KallidonisDepartment of Urology, University of Patras Medical School, University of Patras, Rio, 26500, Patras, Greece.
Dimitris ManolopoulosSchool of Social Sciences, Hellenic Open University, Athens, Greece.
Anastasios MagoutasSchool of Social Sciences, Hellenic Open University, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the potential opportunities and possible competitiveness of Avatera robotic system (ARS) (Avateramedical, Germany), and perform predictive cost-analysis for its implementation and dissemination. MATERIAL AND

methodsOur study employed a projective quantitative research design. SWOT (strengths, weaknesses, opportunities, threats) analysis was used to map ARS internal competencies towards external contexts, and potential opportunities and risks in the robotic market. The ARS purchase and procedural costs were evaluated in two different scenarios.

resultsIn the first scenario, setting the purchase cost of the Avatera at around $1.3-1.5 million, a total $400 procedural cost reduction compared to the RAS performed with the da Vinci Xi can be calculated. In the second scenario, with a purchase cos of the ARS of $700.000-800.000 and considering a 5-year period with an annual ARS volume of 500 procedures, only an additional $300 will be attributed to the robot itself. Our projections revealed that for an effective competition the purchase cost of ARS should range between $700.000 and $800.000 during the initial phase of market entry. The marketing strategy of the ARS should be oriented towards countries without any robotic system in operational use, followed by countries where the competition intensity in the marketplace is low.

conclusionThe introduction of new robotic systems will greatly affect and reshape the market of robotic surgery. The ARS has all the technical capacity ensuring the performance of high-quality surgical procedures. A fast spread and implementation of the ARS could be expected should the purchase and maintenance costs be kept low.

Indexed as

Costs and Cost AnalysisHumansRobotic Surgical ProceduresAvatera robotic systemBusiness modelingCost analysisDa VinciRobot-assisted surgerySWOT analysis

Identifiers

PMID34424374
PMCPMC8381715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.